多西他赛注射液及卡培他滨片与奥沙利铂注射液联合应用在食管癌术后化疗中的疗效分析  

Docetaxel injection and Capecitabine tablets combined with Oxaliplatin injection in postoperative chemotherapy for esophageal cancer

作　　者：豆亚伟[1] 吕珊珊 田伟[1] 王宏涛[1] 朱建飞[1] 戴云[1] 罗向晖[1] DOU Yawei LV Shanshan TIAN Wei WANG Hongtao ZHU Jianfei DAI Yun LUO Xianghui(Department of Thoracic Surgery, Shaanxi People＇s Hospital, Xi＇an, 710068, P.R.China Department of Cardiothoracic Surgery, Xijing Hospital, The Fourth Military Medical University, Xi＇an, 710032, P.R.China)

机构地区：[1]陕西省人民医院胸外科,西安710068 [2]空军军医大学西京医院心血管外科,西安710032

出　　处：《中国胸心血管外科临床杂志》2017年第11期853-857,共5页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

摘　　要：目的探讨多西他赛注射液及卡培他滨片与奥沙利铂注射液联合应用对食管癌患者术后化疗的效果。方法回顾性分析2010年6月至2012年12月我院行根治性手术治疗的101例食管癌患者的临床资料,其中男58例、女43例。根据治疗方法的不同将患者分为研究组(58例,男32例、女26例,术后接受多西他赛注射液及卡培他滨片与奥沙利铂注射液联合化疗)和对照组(43例,男26例、女17例,采取多西他赛注射液和卡培他滨片治疗,连续4个疗程),对比两组患者的化疗效果差异。结果化疗前,研究组和对照组患者的血清癌坯抗原(CEA)、糖类抗原125(CA125)、糖类抗原199(CA199)、鳞状细胞癌抗原(SCC)的水平差异无统计学意义(P>0.05);化疗后,研究组患者的血清CEA、CA125、CA199、SCC的水平均显著低于对照组(P<0.05)。研究组患者1年生存率为92.59%、2年生存率70.37%,与对照组的86.49%、54.05%差异无统计学意义(P>0.05);但研究组3年生存率显著高于对照组(57.41%vs.32.43%,P<0.05)。研究组的平均生存时间长于对照组(31个月vs.22个月,P=0.001)。结论多西他赛注射液及卡培他滨片联合奥沙利铂注射液治疗食管癌术后患者能够显著降低患者血清肿瘤标记物的水平,对患者的远期生存有利,但应注意不良反应。Objective To investigate the efficacy of Docetaxel injection and Capecitabine tablets combined with Oxaliplatin injection in chemotherapy for patients after esophageal cancer surgery. Methods We retrospectively analyzed the clinical data of 101 patients with esophageal cancer who underwent radical surgery from June 2010 to December 2012, including 58 males and 43 females. According to the different treatment methods they were divided into a study group （58 patients, 32 males and 26 females, postoperatively receiving Docetaxel injection, Capecitabine tablets, Oxaliplatin injection and chemotherapy） and a control group （43 patients, 26 males and 17 females, taking Docetaxel injection and Capecitabine tablets for 4 consecutive courses）. We compared the difference in the outcomes between the two groups. Results There was no significant difference in the level of serum anticancer antigen （CEA）, carbohydrate antigen 125 （CA125）, carbohydrate antigen 199 （CA199） and squamous cell carcinoma antigen （SCC） before chemotherapy between two groups （P〉0.05）. After chemotherapy, the level of serum CEA, CA125, CA199, SCC in the study group was significantly lower than that in the control group （P〈0.05）. The 1-year survival rate of the study group was 92.59% and the 2-year survival rate was 70.37%, which were not significantly different from those of the control group （P〉0.05）. The 3-year survival rate of the study group was significantly higher than that of the control group （57.41 %vs. 32.43%, P〈0.05）. The mean survival time of the study group was longer than that of the control group （31 monthsvs. 22 months, P=0.001）. Conclusion Docetaxel injection and Capecitabine tablets combined with Oxaliplatin injection for the treatment of esophageal cancer surgery can significantly reduce levels of tumor markers in serum after esophageal cancer surgery, and is favorable for the long-term survival of patients, but adverse reactions should be noted.

关 键 词：多西他赛 卡培他滨 奥沙利铂 食管癌 

分 类 号：R735.1[医药卫生—肿瘤]